{"name": "ViroPharma",
 "permalink": "viropharma",
 "crunchbase_url": "http://www.crunchbase.com/company/viropharma",
 "homepage_url": "http://www.viropharma.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": 201,
 "founded_year": 1994,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "610-458-7300",
 "description": "",
 "created_at": "Tue Sep 15 01:29:05 UTC 2009",
 "updated_at": "Fri Oct 28 03:26:52 UTC 2011",
 "overview": "\u003Cp\u003EViroPharma Incorporated, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases, with a focus on products used by physician specialists or in hospital settings. The company has two marketed products, and three development programs. The company markets and sells Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the U.S. and its territories. Vancocin is a potent antibiotic approved by the U.S. Food and Drug Administration, or the FDA, to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection (CDI), or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. Product Pipeline The company has three development programs. Its first program is for the acute treatment of HAE. The company\u00e2\u20ac\u2122s second clinical development program targets CMV with an initial focus on CMV disease in recipients of hematopoietic stem cell and solid organ transplants. This program is with in the transplant and hospital setting and focuses on diseases treated by physician specialists. The company\u00e2\u20ac\u2122s third program is in preclinical development and targets the treatment and prevention of CDI utilizing the spore form of a non-toxin producing strain of C. difficile (NTCD). In addition, the company has licensed intranasal pleconaril to Schering-Plough who has assumed responsibility for all development and commercialization of pleconaril in the U.S. and Canada. Cinryze The company, in December 2008, submitted a supplemental Biologics Application (sBLA) for Cinryze as a treatment for acute attacks of HAE based on a re-analysis and resubmission of data from a pivotal Phase 3 acute treatment study of Cinryze and interim data from an ongoing open label acute study of the drug. The phase 3 study was a randomized, double blind, placebo controlled multi-center trial in 71 patients evaluating the safety and efficacy of Cinryze for the treatment of HAE attacks. CMV Program The company, in February 2009, announced that its Phase 3 trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant (SCT) patients. The SCT study is a randomized, double-blind, placebo-controlled, multicenter pivotal Phase 3 study in 681 patients who have undergone allogeneic stem cell transplantation. CDI Program The company, in February 2006, announced that the company had entered into a licensing agreement for the rights to develop non-toxigenic strains of C. difficile (NTCD) for the treatment and prevention of CDI. Strategic Relationships Vancocin Capsules and Lilly The company, in November 2004, acquired all rights in the U.S. and its territories to manufacture, market, and sell Vancocin, the oral capsule formulation of vancomycin hydrochloride, as well as rights to certain related vancomycin products, from Lilly. Cytomegalovirus and GlaxoSmithKline The company, in August 2003, entered into a license agreement with GlaxoSmithKline (GSK) under which the company acquired worldwide rights (excluding Japan) to an antiviral compound, maribavir, for the treatment of CMV disease. Under the terms of the agreement, the company has exclusive worldwide rights (excluding Japan) to develop and commercialize maribavir for the prevention and treatment of cytomegalovirus infections related to transplant (including solid organ and hematopoietic stem cell / bone marrow transplantation), congenital transmission, and in patients with HIV infection. Hepatitis C and Wyeth The company, in December 1999, entered into a collaboration and license agreement with Wyeth (formerly American Home Products Corporation) to jointly develop products for use in treating hepatitis C virus in humans. Under the agreement, the company licensed to Wyeth worldwide rights under certain patents and know-how owned by the company or created under the agreement. The company has the right to co-promote these products in the U.S. and Canada and Wyeth would promote the products elsewhere in the world. Wyeth has the right to manufacture any commercial products developed under the agreement. Picornaviruses and Schering-Plough The company, in November 2004, entered into a license agreement with Schering-Plough under which Schering-Plough has assumed responsibility for all future development and commercialization of pleconaril in the U.S. and Canada. Picornaviruses and Sanofi-Aventis The company, in February 2001, received rights under patents owned by Sanofi-Aventis to develop and market all products relating to pleconaril and related compounds for use in picornavirus disease indications in the U.S. and Canada, as well as a right of first refusal for any other indications in the U.S. and Canada. Sales and Marketing The company\u00e2\u20ac\u2122s initial sales organization was established in 2008 to target doctors and hospitals to promote Vancocin. The Vancocin sales force is located solely in the Northeastern the United States. It focuses its activities for Cinryze towards hospitals, allergists, immunologists and home healthcare. Foreign Operations The company conducts business in European countries through wholly-owned subsidiaries. It has operations in Belgium, the United Kingdom, France and Switzerland. Customers The company sells its products directly to wholesale drug distributors and specialty pharmacies/ specialty distributors who then distribute the product to pharmacies, hospitals, patients, physicians, and long term care facilities. Competition The company\u00e2\u20ac\u2122s competitors include CSL Behring, Pharming Group N.V., F. Hoffmann-La Roche, AstraZeneca, Gilead Sciences, Dyax Corp., Shire Pharmaceuticals, Pharming Group N.V., and CSL Behring. History ViroPharma Incorporated was founded in 1994.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       66],
      "assets/images/resized/0005/9762/59762v2-max-150x150.jpg"],
     [[250,
       109],
      "assets/images/resized/0005/9762/59762v2-max-250x250.jpg"],
     [[450,
       197],
      "assets/images/resized/0005/9762/59762v2-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Vincent",
      "last_name": "J. Milano",
      "permalink": "vincent-j-milano",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Charles",
      "last_name": "A. Rowland Jr.",
      "permalink": "charles-a-rowland-jr",
      "image": null}},
   {"is_past": false,
    "title": "COO",
    "person":
     {"first_name": "Daniel",
      "last_name": "B. Soland",
      "permalink": "daniel-b-soland",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [{"price_amount": 585890000.0,
    "price_currency_code": "USD",
    "term_code": null,
    "source_url": "http://www.fiercebiotech.com/press-releases/viropharma-acquire-lev-pharmaceuticals",
    "source_description": "ViroPharma To Acquire Lev Pharmaceuticals ",
    "acquired_year": 2008,
    "acquired_month": 7,
    "acquired_day": 15,
    "company":
     {"name": "Lev Pharmaceuticals",
      "permalink": "lev-pharmaceuticals",
      "image":
       {"available_sizes":
         [[[150,
            32],
           "assets/images/resized/0014/9972/149972v1-max-150x150.png"],
          [[219,
            47],
           "assets/images/resized/0014/9972/149972v1-max-250x250.png"],
          [[219,
            47],
           "assets/images/resized/0014/9972/149972v1-max-450x450.png"]],
        "attribution": null}}},
   {"price_amount": 164000000.0,
    "price_currency_code": "USD",
    "term_code": "cash_and_stock",
    "source_url": "http://www.fiercebiotech.com/story/viropharma-inks-164m-deal-buy-orphan-drug-biotech/2011-10-27?utm_medium=rss\u0026utm_source=rss",
    "source_description": "ViroPharma inks $164M deal to buy orphan drug biotech",
    "acquired_year": 2011,
    "acquired_month": 10,
    "acquired_day": 27,
    "company":
     {"name": "DuoCort Pharma",
      "permalink": "duocort-pharma",
      "image":
       {"available_sizes":
         [[[150,
            67],
           "assets/images/resized/0015/9863/159863v1-max-150x150.png"],
          [[188,
            85],
           "assets/images/resized/0015/9863/159863v1-max-250x250.png"],
          [[188,
            85],
           "assets/images/resized/0015/9863/159863v1-max-450x450.png"]],
        "attribution": null}}}],
 "offices":
  [{"description": "",
    "address1": "730 Stockton Drive",
    "address2": "",
    "zip_code": "19341",
    "city": "Exton",
    "state_code": "PA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}